产品说明书

Deoxycorticosterone Acetate

Print
Chemical Structure| 56-47-3 同义名 : 醋酸去氧皮质酮 ;11-Deoxycorticosterone acetate;DOC acetate;DOCA;Cortexone acetate
CAS号 : 56-47-3
货号 : A947730
分子式 : C23H32O4
纯度 : 98%
分子量 : 372.498
MDL号 : MFCD00003660
存储条件：

粉末 Sealed in dry,Room Temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 16 mg/mL(42.95 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：

IP 2% DMSO+2% Tween80+30% PEG300+water 1 mg/mL clear

PO 0.5% CMC-Na 30 mg/mL suspension

生物活性
描述 Deoxycorticosterone acetate (DOCA) is a steroid hormone produced by the adrenal gland that possesses mineralocorticoid activity and acts as a precursor to aldosterone. Myocardial stiffness was increased and left ventricular compliance significantly diminished in the DOCA control group, and these changes were attenuated by epicatechin treatment[3]. The systolic blood pressure of non-treated 6-week-old Sprague-Dawley strain rats was gradually increased by DOCA-salt treatment from 137±2 mmHg to 195±7 mmHg at 10 weeks of age[4]. DOCA-escape in the rat is associated with specific alteration of sodium transport in the collecting duct system[5].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01186484 Prostatic Neoplasms Phase 1 Completed - Japan ... 展开 >> Fukuoka, Japan Kashiwa, Japan Koto-Ku, Japan Sunto, Japan Yokohama, Japan 收起 <<
NCT03082339 - Recruiting March 31, 2018 Germany ... 展开 >> University Giessen Recruiting Gießen, Germany, 35394 Contact: Matthias Hecker, MD          Neurologische Klinik Bad Salzhausen Recruiting Nidda, Germany, 63667 Contact: Dirk Bandorski, MD          Contact: Jens Allendörfer, MD 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.68mL

0.54mL

0.27mL

13.42mL

2.68mL

1.34mL

26.85mL

5.37mL

2.68mL
参考文献

[1]Borde P, Mohan M, et al. Effect of myricetin on deoxycorticosterone acetate (DOCA)-salt-hypertensive rats. Nat Prod Res. 2011 Sep;25(16):1549-59.

[2]Underwood KA, McCutcheon NB, et al. The effects of fludrocortisone acetate and deoxycorticosterone acetate on salt appetite in mice. Physiol Behav. 1993 Oct;54(4):671-5.

[3]Jackson D, Connolly K, Batacan R, Ryan K, Vella R, Fenning A. (-)-Epicatechin Reduces Blood Pressure and Improves Left Ventricular Function and Compliance in Deoxycorticosterone Acetate-Salt Hypertensive Rats. Molecules. 2018 Jun 22;23(7):1511.

[4]Ito H, Majima M, Nakajima S, Hayashi I, Katori M, Izumi T. Effect of prolonged administration of a urinary kinase inhibitor, ebelactone B on the development of deoxycorticosterone acetate-salt hypertension in rats. Br J Pharmacol. 1999 Feb;126(3):613-20.

[5]Sonnenberg H. Proximal and distal tubular function in salt-deprived and in salt-loaded deoxycorticosterone acetate-escaped rats. J Clin Invest. 1973 Feb;52(2):263-72.